Correlation Between FrontView REIT, and BioCryst Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both FrontView REIT, and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining FrontView REIT, and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between FrontView REIT, and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on FrontView REIT, and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in FrontView REIT, with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of FrontView REIT, and BioCryst Pharmaceuticals.
Diversification Opportunities for FrontView REIT, and BioCryst Pharmaceuticals
0.29 | Correlation Coefficient |
Modest diversification
The 3 months correlation between FrontView and BioCryst is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding FrontView REIT, and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and FrontView REIT, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on FrontView REIT, are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of FrontView REIT, i.e., FrontView REIT, and BioCryst Pharmaceuticals go up and down completely randomly.
Pair Corralation between FrontView REIT, and BioCryst Pharmaceuticals
Considering the 90-day investment horizon FrontView REIT, is expected to under-perform the BioCryst Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, FrontView REIT, is 1.31 times less risky than BioCryst Pharmaceuticals. The stock trades about -0.21 of its potential returns per unit of risk. The BioCryst Pharmaceuticals is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 753.00 in BioCryst Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of 33.00 from holding BioCryst Pharmaceuticals or generate 4.38% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
FrontView REIT, vs. BioCryst Pharmaceuticals
Performance |
Timeline |
FrontView REIT, |
BioCryst Pharmaceuticals |
FrontView REIT, and BioCryst Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with FrontView REIT, and BioCryst Pharmaceuticals
The main advantage of trading using opposite FrontView REIT, and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if FrontView REIT, position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.FrontView REIT, vs. Broadstone Net Lease | FrontView REIT, vs. Triton International Limited | FrontView REIT, vs. Global Net Lease | FrontView REIT, vs. Lendlease Global Commercial |
BioCryst Pharmaceuticals vs. TG Therapeutics | BioCryst Pharmaceuticals vs. Axsome Therapeutics | BioCryst Pharmaceuticals vs. Seres Therapeutics | BioCryst Pharmaceuticals vs. Madrigal Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |